Form 4: Immuneering Director and 10% Owner Peter Feinberg Increases Stake with Significant Share Purchase

Immuneering Corp. Director and 10% Owner Peter Feinberg has increased his beneficial ownership in the company by purchasing 25,000 shares of Class A Common Stock.

Summary

• Peter Feinberg, a Director and 10% Owner of Immuneering Corp. (IMRX), acquired 25,000 shares of Class A Common Stock on June 18, 2025.
• The shares were purchased at a weighted average price of $2.5275 per share, with individual trades executed within a price range of $2.07 to $2.96.
• This transaction was conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this acquisition, Mr. Feinberg's direct beneficial ownership stands at 136,766 shares.
• Additionally, he indirectly beneficially owns 392,242 shares through PF Associates L.P., 476,615 shares through PEF LLC, and 115,441 shares through S4K Investments LLC, totaling 984,298 indirect shares.
• His total beneficial ownership in Immuneering Corp. after this transaction is 1,121,064 shares of Class A Common Stock.

Sentiment

Score: 8

Explanation: The purchase of a significant number of shares by a director and 10% owner, especially under a 10b5-1 plan, indicates strong insider confidence and is generally viewed very positively by the market.

Positives

• A significant purchase of 25,000 shares by Peter Feinberg, a Director and 10% Owner, signals strong insider confidence in Immuneering Corp.'s future prospects and valuation.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned investment strategy rather than a reactive trade, which can be viewed positively for its transparency and adherence to best practices.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic outlook, focusing solely on an insider's share acquisition.

Management Comments

• "This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.07 to $2.96. The price reported in this column reflects the weighted average purchase price."
• "Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price."
• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This insider purchase by a director and significant shareholder of Immuneering Corp. is a company-specific event. While it doesn't directly reflect broader industry trends, insider buying can signal confidence in a company's specific prospects within its sector, potentially indicating a belief that the stock is undervalued or that positive developments are anticipated.

Comparison to Industry Standards

• This document reports an insider transaction and does not contain information suitable for comparison to global industry benchmarks, specific comparable companies, projects, or results.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal, potentially increasing confidence in the stock and its future performance.

Key Dates

Recommendation

Keywords

Immuneering Corp, IMRX, Peter Feinberg, insider trading, Form 4, beneficial ownership, stock purchase, director, 10% owner, equity acquisition, Rule 10b5-1